A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing ...

The global automated nucleic acid extraction market size was valued at US$ 3.6 Bn in 2025 and is projected to reach US$ 11.7 ...

American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a ...

A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple ...

Across all included studies, AI-based diagnostic systems demonstrated high overall accuracy. When measured against expert ...

Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for ...

A blood test, combined with an ultrathin material derived from graphite, could significantly advance efforts to detect ...

Project LiBRha aims to improve pediatric STS diagnosis and treatment through comprehensive molecular testing and liquid biopsy integration. The initiative involves 18 centers and partnerships with the ...

Genomate Health, the U.S.-based precision medicine company transforming cancer care through its proprietary computational reasoning technology, today announced its acquisition of Oncompass Medicine.

Bayer to acquire AT-01 & AT-05, investigational molecular imaging agents for the diagnosis of cardiac amyloidosis from Attralus: Berlin, Germany Wednesday, January 14, 2026, 11:00 ...